Fri, 05 Mar 2021

TauRx announces completion of Phase 3 study enrolment for the first tau-based disease modifying treatment for Alzheimer's disease

Aberdeen, Scotland and Singapore [January 11, 2020] - TauRx Pharmaceuticals Ltd today announced it has completed patient enrolment of the LUCIDITY study (NCT03446001) ahead of schedule, despite delays due to the COVID-19 pandemic. TauRx is pleased to be presenting its latest trial results at Biotech Showcase™ 2021 during the J.P. Morgan 39th Annual Healthcare Conference 2021. LUCIDITY is the only late-stage study targeting the tau pathology of Alzheimer's disease. It aims to confirm hydromethylthionine as the first tau-based disease modifying treatment for Mild Cognitive Impairment and Mild-Moderate AD.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • TauRx Pharmaceuticals Ltd today announced it has completed patient enrolment of the LUCIDITY study (NCT03446001) ahead of schedule, despite delays due to the COVID-19 pandemic.
  • TauRx is pleased to be presenting its latest trial results at Biotech Showcase™ 2021 during the J.P. Morgan 39th Annual Healthcare Conference 2021.
  • If the efficacy of hydromethylthionine is confirmed, it will open up a completely new treatment direction for a devastating disease which has so far defied all efforts to bring it under control.

Click image above to view full announcement.

Contacts:

TauRx Media

r.andersen@taurx.com

Source: TauRx

Distributed by: Reportable, Inc.

More Scotland News

Access More

Sign up for Scotland News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!